Comprehensive analysis of blood tryptophan metabolites and fatty acids in patients with lung cancer treated with immune checkpoint inhibitors

Comprehensive analysis of blood tryptophan metabolites and fatty acids in patients with lung cancer treated with immune checkpoint inhibitors - Tryptophan metabolites and fatty acids in ICI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039188

Enrollment

200

Registered

2020-01-20

Start date

2019-06-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically diagnosed non-small cell lung cancer patients who received immune checkpoint inhibitors

Exclusion criteria

Exclusion criteria: Insufficient blood samples.

Design outcomes

Primary

Measure	Time frame
Levels of blood tryptophan metabolites and fatty acids	—

Countries

Japan

Contacts

Public ContactMasato Karayama

Hamamatsu University School of Medicine Department of Chemotherapy

karayama@hama-med.ac.jp053-435-2111

Outcome results